GammaDelta Therapeutics Ltd has appointed Michael Koslowski, an experienced research executive, as chief medical officer to oversee the development of its immunotherapy portfolio. Dr Koslowski was most recently CMO of Mission Therapeutics Ltd where he was responsible for development of the company’s pipeline of deubiquitinating enzyme inhibitors. Prior to this, he led early drug development at Glenmark Pharmaceuticals Ltd. GammaDelta Therapeutics has developed a technology platform based on gamma delta T cells for the treatment of cancer.
GammaDelta Therapeutics announced the appointment on 18 June 2018.
Evernow Publishing Ltd 2018.